These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31002882)

  • 1. Different therapeutic regimens in the treatment of metastatic prostate cancer by performing a Bayesian network meta-analysis.
    Zhang Q; Cheng H; Wang Y; Tian Y; Xia J; Wang Y; Zhou X; Meng X; Wang Y; Gu M; Song N
    Int J Surg; 2019 Jun; 66():28-36. PubMed ID: 31002882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
    J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
    Greenberger BA; Zaorsky NG; Den RB
    Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
    Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
    JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of androgen deprivation with radiotherapy for high-risk or locally advanced prostate cancer: A network meta-analysis.
    Petrelli F; De Stefani A; Vavassori I; Motta F; Luciani A; Trevisan F
    Tumori; 2023 Aug; 109(4):424-429. PubMed ID: 36756996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis.
    Wang Y; Qin Z; Wang Y; Chen C; Wang Y; Meng X; Song N
    Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29263146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can patients with low-risk prostate cancer really benefit from radical treatment?: A systematic review and network meta-analysis.
    Zhen L; Zhien Z; Shengmin Y; Hanzhong L; Xingcheng W; Yi Z; Yi Q; Lin M; Yuliang C; Tianrui F; Weigang Y
    Andrologia; 2021 Oct; 53(9):e14122. PubMed ID: 34319588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer?-evidence from a meta-analysis.
    Xiao M; Cong R; Zhang Q; Xiang W; Xiao H
    Ann Palliat Med; 2020 May; 9(3):648-660. PubMed ID: 32312070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison Between Low-Dose-Rate Brachytherapy With or Without Androgen Deprivation, External Beam Radiation Therapy With or Without Androgen Deprivation, and Radical Prostatectomy With or Without Adjuvant or Salvage Radiation Therapy for High-Risk Prostate Cancer.
    Ciezki JP; Weller M; Reddy CA; Kittel J; Singh H; Tendulkar R; Stephans KL; Ulchaker J; Angermeier K; Stephenson A; Campbell S; Haber GP; Klein EA
    Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):962-975. PubMed ID: 28333019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. International Multicenter Validation of an Intermediate Risk Subclassification of Prostate Cancer Managed with Radical Treatment without Hormone Therapy.
    Berlin A; Moraes FY; Sanmamed N; Glicksman R; Koven A; Espin-Garcia O; Leite ETT; Silva JLF; Gadia R; Nesbitt M; Catton CN; Kaffenberger S; Salami SS; Morgan TM; Hearn JWD; Jackson WC; Mehra R; Chung P; Fleshner NE; Zumsteg ZS; Dess RT; Feng FY; Finelli A; Spratt DE
    J Urol; 2019 Feb; 201(2):284-291. PubMed ID: 30153435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.
    Lee W; Lim B; Kyung YS; Kim CS
    Int J Urol; 2022 May; 29(5):414-420. PubMed ID: 35133691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor.
    Grossfeld GD; Li YP; Lubeck DP; Broering JM; Mehta SS; Carroll PR
    J Urol; 2002 Aug; 168(2):530-5. PubMed ID: 12131303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and Prognostic Factors in Men Receiving Androgen Deprivation Therapy for Prostate Cancer Recurrence after Radical Prostatectomy.
    Ravi P; Karnes RJ; Rangel LJ; Pagliaro LC
    J Urol; 2018 Nov; 200(5):1075-1081. PubMed ID: 29709664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
    Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
    Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies.
    Touijer KA; Karnes RJ; Passoni N; Sjoberg DD; Assel M; Fossati N; Gandaglia G; Eastham JA; Scardino PT; Vickers A; Cozzarini C; Montorsi F; Briganti A
    Eur Urol; 2018 Jun; 73(6):890-896. PubMed ID: 29042125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
    Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
    Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
    Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
    Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?
    Taguchi S; Fukuhara H; Morikawa T; Matsumoto A; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
    Jpn J Clin Oncol; 2016 Dec; 46(12):1143-1147. PubMed ID: 27620729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.